Thu, Apr 25, 2024
A A A
Welcome Guest
Free Trial RSS pod
Get FREE trial access to our award winning publications
Industry Updates

Dr. Craig Gordon launches alternative investment firm GordonMD Global Investments

Wednesday, September 08, 2021
Opalesque Industry Update, for New Managers - Craig Gordon, MD, a licensed physician with over a decade of buy-side experience managing global biopharmaceutical portfolios, has launched GordonMD Global Investments. The U.S.-based firm is focused on investments in private and publicly traded global growth and innovative biopharma companies primarily located in the U.S., Japan, and Europe.

GordonMD Global Investments stands apart from other equity managers, including those focused on biopharmaceutical or similar sector and industries. The firm's perspective is derived from Dr. Gordon's medical knowledge and training combined with his over 10 years of experience at The Capital Group, where he served as an Equity Investment Analyst, built and managed an on average over $7 billion AUM portfolio across various mandates, and assisted with oversight of additional multi-billion dollar AUM portfolios.

"The launch of GordonMD Global Investments is the culmination of my decades of experience as a portfolio manager, investment analyst and physician. At GordonMD Global Investments we employ my proprietary analysis to target truly innovative companies with best-in-class assets that move clinically with the potential not only to change the standard of care but also to generate outsized returns. The firm combines my medical and investing acumen to create a singular advantage for institutional and accredited high-net-worth investors," said Craig Gordon, MD, Founder, CEO, and CIO of GordonMD Global Investments.

Prior to establishing his own firm, Dr. Gordon worked at The Capital Group for 10+ years, where he was an Equity Investment Analyst and built his own portfolio and established a successful track record in Private Placements and with multiple fund mandates, including U.S. Growth, Global Growth and Small Cap. Prior to The Capital Group, he worked for the Cowen Group in New York as a Biotechnology Equity Research Analyst and Associate. Dr. Gordon lives and works in Los Angeles but frequently visits management teams and attends conferences across the world. He earned an MBA from Duke University, a Doctor of Medicine from the University of Miami Miller School of Medicine, and a B.A. in Economics from Cornell University.

The firm's service providers include Jefferies, Bank of America, SS&C, Seward & Kissel LLP, Constellation Consulting Services LLC, and Goldman Sachs.


Press release
Bg

Article source - Opalesque is not responsible for the content of external internet sites

What do you think?

   Use "anonymous" as my name    |   Alert me via email on new comments   |   
Previous Opalesque Exclusives                                  
Previous Other Voices                                               
Access Alternative Market Briefing

 



  • Top Forwarded
  • Top Tracked
  • Top Searched
  1. KKR raises $6.4bn for the largest pan-Asia infrastructure fund[more]

    Laxman Pai, Opalesque Asia: The New York-based global investment firm KKR has raised a record $6.4bn for its second Asia-focused infrastructure fund, underlining investors' continued appetite for private markets. According to a media release from the alternative assets manager, the figure top

  2. Bucking the trend, top hedge fund makes plans for a second SPAC[more]

    From Institutional Investor: SPACs aren't dead. At least not to the folks at Cormorant Asset Management. The life sciences firm, whose hedge fund topped its peers in 2023, is confident it will match the success of its first blank-check company. Last week, the life sciences and biopharma speciali

  3. Benefit Street Partners closes fifth fund on $4.7 billion[more]

    Bailey McCann, Opalesque New York: Benefit Street Partners has closed its fifth flagship direct lending vehicle, BSP Debt Fund V, with $4.7 billion of investable capital across the strategy. Benefit Street invests primarily in privately originated, floating rate, senior secured loans. The fun

  4. 4 hedge fund themes that are working in 2024[more]

    From The Street: A poor earnings report from Tesla (TSLA) has not hurt the indexes on Thursday. The decline in Tesla stock, which is losing its position in the Magnificent Seven pantheon, is more than offset by strong earnings from IBM (IBM) and ServiceNow (NOW) . In addition, the much higher-t

  5. Opalesque Exclusive: A global macro fund eyes opportunities in bonds[more]

    Bailey McCann, Opalesque New York for New Managers: Munich-based ThirdYear Capital rebounded in 2023, following a tough year for global macro. The firm's flagship ART Global Macro strategy finished the year up 1